Esperion Therapeutics Files 8-K on Financials
Ticker: ESPR · Form: 8-K · Filed: May 6, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k
Related Tickers: ESPR
TL;DR
Esperion Therapeutics dropped an 8-K on May 6th - check it for financial updates.
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with no specific financial figures or operational details provided in this initial summary.
Why It Matters
This 8-K filing signals an update on Esperion Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not inherently present new risks.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- May 6, 2025 (date) — Date of Report
- 3891 Ranchero Drive, Suite 150 (address) — Principal Executive Offices
- Ann Arbor, MI (location) — Principal Executive Offices City and State
- 48108 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing is related to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not detail the specific financial figures within this summary.
When was this 8-K filing submitted?
The filing was submitted on May 6, 2025.
What is the primary purpose of this 8-K filing for Esperion Therapeutics?
The primary purpose is to report on the company's results of operations and financial condition.
Where are Esperion Therapeutics' principal executive offices located?
Esperion Therapeutics' principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
Does this filing mention any changes to the company's name or address?
The filing notes a former company name, 'HDL THERAPEUTICS INC,' with a date of name change as '20080513,' but does not indicate a change in the current address.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Esperion Therapeutics, Inc. (ESPR).